Panther Biotechnology Reports the Fiscal Year Ended May 2014 And The First Three Quarters Of Fiscal Year 2015 Bringing The Company Current In Its SEC Filing Obligations

CHICAGO, IL and LA JOLLA, CA--(Marketwired - June 15, 2015) - Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today reported financial results for the year ended May 31, 2014 and for the first three quarters of fiscal year 2015. The results for such periods are primarily from our wholly owned subsidiary, Pubco, which is in the business of operating as a filing agent offering both EDGAR and XBRL services for filing and uploading securities filings to the Securities and Exchange Commission.

“The Company is pleased to announce this milestone in our determined effort to bring its financial filings current with Securities and Exchange Commission guidelines,” stated Evan Levine, Chief Executive Officer of Panther. “I would like to personally offer my gratitude for the patience shown by our shareholders and express my appreciation for their support as the Company moves to its next phase of growth with its new line of business, which will be the main focus of the Company. In fiscal year 2015, Panther has executed agreements for three clinical candidates and a platform technology and is continuing to advance its business plan by negotiating new product and financing opportunities.”

Full Year 2014 Operating Results

The Company’s net loss for the fiscal year ending May 31, 2014 was $2,339.00, or $0.00 per share (basic and diluted), compared to a net loss of $6,792.00, or $0.00 per share (basic and diluted), for the same period ending May 31, 2013.

Fiscal 3rd Quarter Operating Results

The Company’s net loss for the quarter ending February 28, 2015 was ($145,112), or ($0.03) per share (basic and diluted), compared to a net profit of $23,504, or $0.00 per share (basic and diluted), for the same period ending February 28, 2014. The cumulative net loss for three quarters ending February 28, 2015 was ($145,249), or ($0.03) per share (basic and diluted), compared to a net profit of $18,732, or $0.00 per share (basic and diluted), for the same period ending February 28, 2014.

The revenue is attributed to a wholly owned subsidiary, Pubco Reporting Services, in Miami, Florida. The results of operations up to February 28, 2015 are insignificant and unrelated to the biotechnology operations of Panther, which is the future of the Company.

ABOUT PANTHER BIOTECHNOLOGY
Panther Biotechnology, Inc. is an entity focused on the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders. The Company is currently developing three clinical candidates, TRF-DOX which is a combination of transferrin glycoproteins with Doxorubicin for targeted delivery to tumors with the reduction of serious side effects; Numonafide, which is a derivative of the widely studied anticancer drug Amonafide, optimized to eliminate toxic metabolites and reduce side effects; and TDZD-8, a kinase inhibitor targeting cancer stem cells. Panther is continuing its acquisition strategy focusing on identifying undervalued companies and clinical assets, including those programs that have missed clinical endpoints, and bringing scientific and medical personnel capable of running the trials and extracting value from the assets.